Share on StockTwits

Stock analysts at Wedbush hoisted their price objective on shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) from $32.00 to $33.00 in a report issued on Monday, American Banking & Market News reports. Wedbush’s price objective would indicate a potential upside of 214.59% from the stock’s previous close.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) traded down 2.76% on Monday, hitting $10.20. The stock had a trading volume of 74,058 shares. La Jolla Pharmaceutical Company has a 52 week low of $3.00 and a 52 week high of $19.50. The stock has a 50-day moving average of $10.62 and a 200-day moving average of $8.57. The company’s market cap is $44.925 billion.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last released its earnings data on Monday, March 31st. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.24) by $0.17. Analysts expect that La Jolla Pharmaceutical Company will post $-1.20 EPS for the current fiscal year.

A number of other analysts have also recently weighed in on LJPC. Analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Separately, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock. Finally, analysts at Chardan Capital initiated coverage on shares of La Jolla Pharmaceutical Company in a research note on Thursday, March 6th. They set a “buy” rating and a $32.00 price target on the stock.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.